| Literature DB >> 32235883 |
Donn J Colby1, Michal Sarnecki2, Dan H Barouch3, Somporn Tipsuk1, Daniel J Stieh4, Eugène Kroon1, Alexandra Schuetz5,6,7, Jintana Intasan1, Carlo Sacdalan1, Suteeraporn Pinyakorn6,7, Pornsuk Grandin5, Hongshuo Song6,7,8, Sodsai Tovanabutra6,7, Zhanna Shubin6,7, Dohoon Kim6,7, Dominic Paquin-Proulx6,7, Michael A Eller6,7, Rasmi Thomas6,7, Mark de Souza1,7, Lindsay Wieczorek7, Victoria R Polonis7, Amélie Pagliuzza9, Nicolas Chomont9, Lauren Peter3, Joseph P Nkolola3, Johan Vingerhoets10, Carla Truyers10, Maria G Pau4, Hanneke Schuitemaker4, Nittaya Phanuphak1, Nelson Michael6,7, Merlin L Robb11,12, Frank L Tomaka13, Jintanat Ananworanich1,6,7,14.
Abstract
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).Entities:
Mesh：
Substances：
Year: 2020 PMID： 32235883 DOI： 10.1038/s41591-020-0774-y
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241